Resveratrol and adipose-derived mesenchymal stem cells are effective in the prevention and treatment of doxorubicin cardiotoxicity in rats

Pediatric Hematology and Oncology

Volumn 30, Issue 3, 2013, Pages 226-238

  Pinarli, Ferda Alpaslan ^a   Turan, Nilüfer N ^b   Pinarli, Faruk Güçlü ^c   Okur, Arzu ^c   Sönmez, Devrim ^d   Ulus, Tulga ^e   Oǧuz, Aynur ^c   Karadeniz, Ceyda ^c   Delibaşi, Tuncay ^a  

^a Di kapi Yildirim Beyazit Research Hospital   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d TDV 29 Mayis Hospital   (Turkey)

^e TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Adipose derived mesenchymal stem cells; Cardiotoxicity; Doxorubicin; Resveratrol

Indexed keywords

ALPHA INTEGRIN; BROXURIDINE; CD11B ANTIGEN; CD45 ANTIGEN; DOXORUBICIN; GLYCOPROTEIN P 15095; HERMES ANTIGEN; RESVERATROL; THY 1 ANTIGEN; TROPONIN I;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADIPOSE DERIVED STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL LABELING; CELL REGENERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; RAT; THERAPY EFFECT;

ADIPOSE TISSUE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DOXORUBICIN; FEMALE; HEART DISEASES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; RATS, WISTAR; STILBENES;

EID: 84875200781     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.762962     Document Type: Article

References (50)

1. Simbre VC, Dufy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy implications for children. Pediatr Drugs. 2005;7:187-202.
2. Mertens AC. Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer. 2007;48:723-726.
3. Yeh JM, Nekhlyudov L, Goldie SJ, et al. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010;152:409-417.
4. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108:619-628.
5. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genesa report from the children's oncology group. J Clin Oncol. 2012;30:1415-1421.
6. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab. 2009;10:530-546.
7. Danz ED, Skramsted J, Henry N, et al. Resveratrol prevents doxorubicin cardiotoxicity through mi-tochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 2009;46:1589-1597.
8. Tatlidede E, Şehirli O, Velioglu-Ö vünç A, et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res. 2009;43:195-205.
9. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011;90:538-545.
10. Prezioso L, Tanzi S, Galaverna F, et al. Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease? Cardiovasc Hematol Agents Med Chem. 2010;8:55-75.
11. Li YM, Guo YP, Liu Y. Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells. J Cell Mol Med. 2010;14:2630-2632.
12. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115:155-162.
13. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:4517-4522.
14. Sieswerda E, van Dalen EC, Postma A, et al. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2011;7:CD008011.
15. Kaushal S, Jacobs JP, Gossett JG, et al. Innovation in basic science: stem cells and their role in the treatment of paediatric cardiac failure-opportunities and challenges. Cardiol Young. 2009;19: 74-84.
16. Christiansen S. Clinical management of doxorubicin-induced heart failure. J Cardiovasc Surg. 2011;52:133-138.
17. Bernstein HS, Srivastava D. Stem cell therapy for cardiac disease. Pediatr Res. 2012;71:491-499.
18. Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 2004;13:436-448.
19. Cowan CM, Shi YY, Aalami OO, et al. Adipose-derived adult stromal cells heal critical-size mouse calvarial defects. Nat Biotechnol. 2004;22:560-567.
20. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol. 2001;155;197-212.
21. Bryja J, Konecny A. Fast sex identifcation in wild mammals using PCR amplifcation of the Sry gene. Folia Zool. 2003;52:269-274.
22. Ise H, Nikaido T, Negishi N, et al. Efective hepatocyte transplantation using rat hepatocytes with low asialoglycoprotein receptor expression. Am J Pathol. 2004;165:501-510.
23. Marques FZ, Markus MA, Morris BJ. Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefts. Int J Biochem Cell Biol. 2009;41:2125-2128.
24. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, et al. Resveratrol enhances the cytotoxic profle of doc-etaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011;44:591-601.
25. Kweon SH, Song JH, Kim TS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun. 2010;395:104-110.
26. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324: 98-102.
27. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-292.
28. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigensonhuman marrow-derived mesenchy-mal cells are detected by monoclonal antibodies. Bone. 1992;13:69-80.
29. Zhu Y, Liu T, Song K, et al. Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008;26:664-675.
30. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108:3938-3944.
31. Van Linthout S, Stamm C, Schultheiss HP, Tschöpe C. Mesenchymal stem cells and infammatory cardiomyopathy: cardiac homing and beyond. Cardiol Res Pract. 2011;2011:757154.
32. Lin YC, Leu S, Sun CK, et al. Early combined treatment with sildenafl and adipose-derived mes-enchymal stem cells preserves heart function in rat dilated cardiomyopathy. J Transl Med. 2010;8:88.
33. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705.
34. Qi Z, Zhang Y, Liu L, et al. Mesenchymal stem cells derived from diferent origins have unique sensitivities to diferent chemotherapeutic agents. Cell Biol Int. 2012; Jun 14. [Epub ahead of print].
35. Strauer BE, Brehm M, Schannwell CM. Te therapeutic potential of stem cells in heart disease. Cell Prolif. 2008;41:126-145.
36. Zeinaloo AA, Zanjani KS, Bagheri MM, et al. Intracoronary administration of autologous mes-enchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant. 2011;15:E183-E186.
37. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112:1128-1135.
38. Nakanishi C, Yamagishi M, Yamahara K, et al. Activation of cardiac progenitor cells through paracrine efects of mesenchymal stem cells. Biochem Biophys Res Commun. 2008:374:11-16.
39. Banas A, Teratani T, Yamamoto Y, et al. IFATS Collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver Injury. Stem Cells. 2008;26:2705-2712.
40. Zhang J, Li GS, Li GC, et al. Autologous mesenchymal stem cells transplantation in adriamycin-induced cardiomyopathy. Chin Med J. 2005;118:73-76.
41. Chen Y, Liu W, Li W, et al. Autologous bone marrow mesenchymal cell transplantation improves left ventricular function in a rabbit model of dilated cardiomyopathy. Exp Mol Pathol. 2010;88:311-315.
42. Di GH, Jiang S, Li FQ, et al. Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model. Cytotherapy. 2012;4:412-422.
43. Mu Y, Cao G, Zeng Q, Li Y. Transplantation of induced bone marrow mesenchymal stem cells improves the cardiac function of rabbits with dilated cardiomyopathy via upregulation of vascular en-dothelial growth factor and its receptors. Exp Biol Med. 2011;236:1100-1107.
44. Chiu R. Bone-marrow stem cells as a source for cell therapy. Heart Fail Rev. 2003;8:247-251.
45. Singla DK, Ahmed A, Singla R, Yan B. Embryonic stem cells improve cardiac function in doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. Cell Transplant. 2012;Mar 22. [Epub ahead of print]
46. Sun CK, Chang LT, Sheu JJ, et al. Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009;37:1197-1205.
47. Rupp S, Bauer J, Tonn T, et al. Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old-child with dilated cardiomyopathy. Pediatr Transplant. 2009:13:620-623.
48. Zeinaloo AA, Zanjani KS, Khosroshahi AG. Further follow up of the cardiomyopathic patient treated by intracoronary administration of autologous mesenchymal stem cells. Pediatr Transplant. 2011;15:442.
49. Rivas J, Menéndez JJ, Arrieta R, et al. Usefulness of intracoronary therapy with progenitor cells in patients with dilated cardiomyopathy: bridge or alternative to heart transplantation? An Pediatr. 2011;74:218-225.
50. Olguntürk R, Kula S, Sucak GT, et al. Peripheric stem cell transplantation in children with dilated cardiomyopathy: preliminary report of frst two cases. Pediatr Transplant. 2010;14:257-260.